Pittsburgh – Mylan Inc. recently had received FDA approval for the generic hypertension drug, Teveten.

Teveten, or eprosartan mesylate, is marketed by Abbott Laboratories Inc. Mylan said Teveten’s U.S. sales totaled $4.9 million over the year ended Sept. 30.

Mylan said it is now shipping generic Teveten in strengths of 400 milligrams and 600 milligrams. It will have six months of marketing exclusivity.

For more information about Mylan, please visit www.mylan.com. To buy Teveten online, please check the product details here.

This entry was posted on Wednesday, December 28th, 2011 at 7:12 am and is filed under New FDA Approval. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.